GeneDx Holdings Corp. Class A Common Stock (WGS) Stock
Key stats
- Market cap
- $1.65B
- Price / Earnings ratio
- -14.8x
- EPS (TTM)
- -$3.78
- Volume
- Loading
- 52-week high
- $170.87
- 52-week low
- $32.21
Source: third-party data provider, as of November 13, 2026
Compare with WGS
Recent news

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
WGS

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
WGS

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
WGS

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
WGS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.64
- MACD 12/26/9
- -3.70
- EMA 9 of MACD
- -3.23
- MACD histogram
- -0.46
- SMA 50
- $75.23
- Price below SMA 50
- EMA 50
- $70.20
- Price below EMA 50
- SMA 200
- $70.34
- Price below SMA 200
- EMA 200
- $80.99
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
WGS

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
WGS

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
WGS

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
WGS

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
WGS

3 Promising Genomics Stocks in the Spotlight in 2026
3 Promising Genomics Stocks in the Spotlight in 2026
WGS

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
WGS

GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
WGS

Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
WGS

GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
WGS
News tone: automated (AI) classification of the article's content, not a price prediction.
About GeneDx Holdings Corp. Class A Common Stock
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Katherine A. Stueland | CEO & Director | 1976 |
| Mr. Kevin Feeley CPA | Chief Financial Officer | 1981 |
| Dr. Bryan M. Dechairo Ph.D. | Chief Technology & Innovation Officer | 1973 |
| Mr. Mark A. Gardner M.B.A. | President | 1966 |
| Ms. Sabrina V. Dunbar | Director of Investor Relations & Communications | — |
| Ms. Heidi C. Chen J.D. | Chief Legal Officer | 1967 |
| Ms. Jami Biliboaca | Chief People Officer | — |
| Ms. Melanie Duquette | Chief Growth Officer | — |
| Ms. Lisa Gurry | Chief Business Officer | — |
| Ms. Linda Genen M.D., M.P.H. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.64
- MACD 12/26/9
- -3.70
- EMA 9 of MACD
- -3.23
- MACD histogram
- -0.46
- SMA 50
- $75.23
- Price below SMA 50
- EMA 50
- $70.20
- Price below EMA 50
- SMA 200
- $70.34
- Price below SMA 200
- EMA 200
- $80.99
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $83.00
- Average
- $84.00
- High
- $85.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.9 | -19.5 | -13.5 | -4.0 | -20.5 | +32.0 | -9.2 | +25.0 | -14.8 | -2.7 | -14.0 |



